BRIEF-Bioversys Announces Expansion Of Strategic Collaboration With GSK And Extension Of Its Series C Round By CHF 12.3 Million

Reuters05-07

May 7 (Reuters) - Bioversys:

* BIOVERSYS ANNOUNCES EXPANSION OF STRATEGIC COLLABORATION WITH GSK AND EXTENSION OF ITS SERIES C ROUND BY CHF 12.3 MILLION

* BIOVERSYS : STRATEGIC COLLABORATION WITH GSK EXPANDED TO ACCELERATE CLINICAL DEVELOPMENT OF ALPIBECTIR FOR TREATMENT OF TUBERCULOSIS

* BIOVERSYS: GSK TO PARTICIPATE IN SERIES C EXTENSION WITH EQUITY INVESTMENT

* BIOVERSYS: SERIES C FINANCING ROUND EXTENDED OVERALL BY CHF 12.3 MILLION TO CHF 44.9 MILLION

Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2433221049?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-05-07 14:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2433221049","market":"us","top_or_hot":-1,"title":"BRIEF-Bioversys Announces Expansion Of Strategic Collaboration With GSK And Extension Of Its Series C Round By CHF 12.3 Million","media":"Reuters","content":"<html><body><p>May 7 (Reuters) - Bioversys:</p><p>   * BIOVERSYS ANNOUNCES EXPANSION OF STRATEGIC COLLABORATION WITH GSK AND EXTENSION OF ITS SERIES C ROUND BY CHF 12.3 MILLION</p><p>   * BIOVERSYS : STRATEGIC COLLABORATION WITH GSK EXPANDED TO ACCELERATE CLINICAL DEVELOPMENT OF ALPIBECTIR FOR TREATMENT OF TUBERCULOSIS</p><p>   * BIOVERSYS: GSK TO PARTICIPATE IN SERIES C EXTENSION WITH EQUITY INVESTMENT</p><p>   * BIOVERSYS: SERIES C FINANCING ROUND EXTENDED OVERALL BY CHF 12.3 MILLION TO CHF 44.9 MILLION</p><p>Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Bioversys Announces Expansion Of Strategic Collaboration With GSK And Extension Of Its Series C Round By CHF 12.3 Million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Bioversys Announces Expansion Of Strategic Collaboration With GSK And Extension Of Its Series C Round By CHF 12.3 Million\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-05-07 14:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>May 7 (Reuters) - Bioversys:   * BIOVERSYS ANNOUNCES EXPANSION OF STRATEGIC COLLABORATION WITH GSK AND EXTENSION OF ITS SERIES C ROUND BY CHF 12.3 MILLION   * BIOVERSYS : STRATEGIC COLLABORATION WITH ...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2433221049","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2433221049","pubTimestamp":1715063436,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"May 7  - Bioversys:   * BIOVERSYS ANNOUNCES EXPANSION OF STRATEGIC COLLABORATION WITH GSK AND EXTENSION OF ITS SERIES C ROUND BY CHF 12.3 MILLION   * BIOVERSYS : STRATEGIC COLLABORATION WITH GSK EXPANDED TO ACCELERATE CLINICAL DEVELOPMENT OF ALPIBECTIR FOR TREATMENT OF TUBERCULOSIS   * BIOVERSYS: GSK TO PARTICIPATE IN SERIES C EXTENSION WITH EQUITY INVESTMENT   * BIOVERSYS: SERIES C FINANCING ROUND EXTENDED OVERALL BY CHF 12.3 MILLION TO CHF 44.9 MILLIONFurther company coverage:    ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","LU1829250122.USD":"高盛欧洲核心股票组合Acc","BK4007":"制药","BK4532":"文艺复兴科技持仓","GSK.UK":"葛兰素史克","GSK":"葛兰素史克","BK4585":"ETF&股票定投概念"},"translate_title":"简介-Bioversys宣布扩大与GSK的战略合作，并将其C轮融资延长1230万瑞士法郎","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GSK":1,"GSK.UK":0.6},"content_text":"May 7 (Reuters) - Bioversys:   * BIOVERSYS ANNOUNCES EXPANSION OF STRATEGIC COLLABORATION WITH GSK AND EXTENSION OF ITS SERIES C ROUND BY CHF 12.3 MILLION   * BIOVERSYS : STRATEGIC COLLABORATION WITH GSK EXPANDED TO ACCELERATE CLINICAL DEVELOPMENT OF ALPIBECTIR FOR TREATMENT OF TUBERCULOSIS   * BIOVERSYS: GSK TO PARTICIPATE IN SERIES C EXTENSION WITH EQUITY INVESTMENT   * BIOVERSYS: SERIES C FINANCING ROUND EXTENDED OVERALL BY CHF 12.3 MILLION TO CHF 44.9 MILLIONFurther company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2433221049"}